Guggenheim Capital LLC grew its position in Bioverativ Inc (NASDAQ:BIVV) by 8.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 403,032 shares of the biotechnology company’s stock after purchasing an additional 31,964 shares during the quarter. Guggenheim Capital LLC owned approximately 0.37% of Bioverativ worth $21,730,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Thrivent Financial For Lutherans acquired a new stake in shares of Bioverativ in the 4th quarter valued at $1,268,000. Amundi Pioneer Asset Management Inc. acquired a new stake in shares of Bioverativ in the 4th quarter valued at $903,000. WINTON GROUP Ltd grew its position in shares of Bioverativ by 172.3% in the 4th quarter. WINTON GROUP Ltd now owns 136,278 shares of the biotechnology company’s stock valued at $7,348,000 after buying an additional 86,223 shares during the last quarter. Burney Co. purchased a new position in shares of Bioverativ in the 4th quarter valued at $309,000. Finally, Allianz Asset Management GmbH grew its position in shares of Bioverativ by 33.6% in the 4th quarter. Allianz Asset Management GmbH now owns 411,187 shares of the biotechnology company’s stock valued at $22,171,000 after buying an additional 103,419 shares during the last quarter. Institutional investors and hedge funds own 97.18% of the company’s stock.
BIVV stock opened at $104.98 on Wednesday. Bioverativ Inc has a 52-week low of $48.14 and a 52-week high of $105.01. The stock has a market cap of $11,360.00 and a price-to-earnings ratio of 38.31.
Bioverativ (NASDAQ:BIVV) last issued its quarterly earnings data on Tuesday, February 13th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.75 by $0.01. Bioverativ had a net margin of 30.43% and a return on equity of 40.99%. The company had revenue of $328.70 million for the quarter, compared to the consensus estimate of $325.89 million. analysts anticipate that Bioverativ Inc will post 3.82 EPS for the current year.
A number of research analysts recently commented on BIVV shares. Zacks Investment Research raised shares of Bioverativ from a “hold” rating to a “buy” rating and set a $60.00 target price on the stock in a research report on Monday, January 1st. Jefferies Group increased their target price on shares of Bioverativ to $79.00 and gave the company a “buy” rating in a research report on Thursday, January 18th. Credit Suisse Group reaffirmed a “neutral” rating and issued a $65.00 target price on shares of Bioverativ in a research report on Thursday, January 18th. Royal Bank of Canada increased their target price on shares of Bioverativ to $68.00 and gave the company a “market perform” rating in a research report on Thursday, January 18th. Finally, Piper Jaffray Companies downgraded shares of Bioverativ from an “overweight” rating to a “neutral” rating in a research report on Monday, January 22nd. Twelve equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $63.83.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Want to see what other hedge funds are holding BIVV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioverativ Inc (NASDAQ:BIVV).
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.